Compare Medtronic PLC (MDT) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Victoria's Secret & Co — how do they compare? Medtronic PLC trades at $83.21 (market cap $106.61B), while Victoria's Secret & Co trades at $88.33 (market cap $6.95B). The key difference: Medtronic PLC is far larger — about 15.3× Victoria's Secret & Co's market cap, and Medtronic PLC pays a 3.46% dividend while Victoria's Secret & Co pays none. Which is the better fit depends on your goals.
| MDT | VSXY | |
|---|---|---|
Market Cap | $106.61B | $6.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $105.35 | $88.50 |
52-Week Low | $73.75 | $18.72 |
Enterprise Value | $125.36B | $9.59B |
Dividend Yield | 3.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
Victoria's Secret (VSXY) trades at $87.49, up 7.42% today, with a bullish technical signal and strong momentum. Recent earnings beats in Q3 2025, Q4 2025, and Q1 2026 highlight improving fundamentals, while international growth and product innovation drive positive sentiment. The stock is near its consensus price target of $88.56, with net cash flow turning positive in 2026 projections.
Outlook remains favorable with analyst consensus at Buy (55.56% of coverage), though valuation multiples like P/E of 32.45 and net margin of 3.12% suggest premium pricing. Risks include competitive pressures and reliance on international expansion, but institutional support and earnings momentum support upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
